Category: GLP-1s

Surprise pregnancies may be an unexpected side effect experienced by women who use Ozempic or other GLP-1 medications, The Washington Post reported April 5.

A small study has found lixisenatide, a GLP-1 made by Sanofi, may slow the progression of Parkinson’s disease, according to findings published April 3 in The New England Journal of Medicine. 

After patients and clinicians reported weeklong back orders of Zepbound, Eli Lilly’s new weight loss drug, the FDA confirmed shortages of two Zepbound solutions. 

Six months after Costco announced its entrance into the healthcare industry with $29 virtual primary care visits, the big box retailer is launching a specialized weight loss program exclusively for its members. 

Physicians estimate up to 15% of people who try GLP-1s — the popular class of anti-obesity medications that includes drugs that include Ozempic and Wegovy — lose less than 5% of their body weight, The Wall Street Journal reported April 1. 

By 2030, between 2.5 million and 3.8 million cases of obstructive sleep apnea can be avoided — a 10.7% reduction in overall prevalence — based on estimates of patients taking Wegoy. 

While the list price for a monthly supply of Ozempic in the U.S. nears $1,000, new research indicates it could be manufactured for less than $5 per month, sparking calls from lawmakers for Novo Nordisk to lower the price of its blockbuster diabetes and…

Among nearly 1 million patients who underwent upper or lower endoscopy procedures, those prescribed GLP-1s, such as Ozempic or Wegovy, were 33% more likely to experience aspiration pneumonia than other patients. 

Nonadherance seems to be a nonissue for patients taking new weight loss drugs, The New York Times reported March 24. 

Another off-label use of GLP-1s, a drug class including Ozempic, Mounjaro and Zepbound, is gaining traction among women seeking to prevent pregnancy complications.